DEFA14A: Seres Therapeutics Corrects Proxy Statement Regarding Executive Compensation Disclosure

Seres Therapeutics files a supplement to its proxy statement to correct an error in the calculation of total shareholder return (TSR) within the Executive Compensation section.

Summary

• Seres Therapeutics has filed a supplement to its definitive proxy statement to correct an error in the calculation of total shareholder return (TSR) within the Executive Compensation section.
• The error occurred in the Pay Versus Performance disclosure, where TSR was incorrectly calculated based on a measurement period commencing on December 31, 2019, instead of December 31, 2021.
• The company is a smaller reporting company and should have included three completed fiscal years in the Pay Versus Performance table, using the latter date as the commencement point.
• The supplement reproduces the Pay Versus Performance disclosure in full, replacing the originally included information.
• Stockholders who have already voted do not need to take any action unless they wish to change their vote.
• The corrected Pay Versus Performance table includes data for the fiscal years ended December 31, 2022, 2023, and 2024, showing summary compensation, compensation actually paid to the PEO and non-PEO NEOs, the value of a $100 initial investment based on TSR, and net income.
• For 2024, the PEO's summary compensation was $2,682,007, and compensation actually paid was $1,906,325, while the average summary compensation for non-PEO NEOs was $1,259,430, and compensation actually paid was $988,401.
• In 2024, a $100 investment would be worth $10.
• For 2023, the PEO's summary compensation was $3,158,336, and compensation actually paid was negative $517,565, while the average summary compensation for non-PEO NEOs was $1,695,799, and compensation actually paid was $260,831.
• In 2023, a $100 investment would be worth $17.
• For 2022, the PEO's summary compensation was $4,006,248, and compensation actually paid was $1,574,321, while the average summary compensation for non-PEO NEOs was $1,706,633, and compensation actually paid was $1,109,334.
• In 2022, a $100 investment would be worth $67.
• Net income for 2024 was $136,000, for 2023 it was negative $113,724,000, and for 2022 it was negative $250,157,000.

Sentiment

Score: 6

Explanation: The sentiment is neutral. While the company corrected an error, the negative compensation for the PEO in 2023 and the need for a correction introduce some negative aspects.

Positives

• The company promptly addressed and corrected the error in the proxy statement.
• The supplement provides clear and detailed information on the corrected Pay Versus Performance disclosure.
• Stockholders who have already voted do not need to take any action unless they wish to change their vote.

Negatives

• The initial error in the proxy statement could have misled investors regarding executive compensation and company performance.
• The negative compensation actually paid to the PEO in 2023 may raise concerns about executive compensation practices.

Risks

• Inaccurate or misleading disclosures in proxy statements can lead to legal and reputational risks.
• Negative perceptions of executive compensation can impact investor confidence and stock price.

Industry Context

The disclosure relates to executive compensation, a topic of increasing scrutiny in corporate governance. Companies are required to provide transparent and accurate information about how executive pay aligns with company performance.

Comparison to Industry Standards

• Pay versus performance disclosures are now standard practice for publicly traded companies, driven by SEC regulations aimed at increasing transparency.
• Companies like Amgen, Biogen, and Vertex Pharmaceuticals, which are also in the biotechnology sector, provide similar disclosures in their proxy statements.
• Benchmarking executive compensation against peers is a common practice to ensure competitiveness and alignment with industry standards.

Stakeholder Impact

• Shareholders are directly impacted by the accuracy of executive compensation disclosures.
• Employees may be affected by perceptions of fairness in executive pay.
• The company's reputation and investor confidence can be influenced by the transparency and accuracy of its disclosures.

Next Steps

• Stockholders are encouraged to vote their shares or provide voting instructions to their broker promptly.
• Stockholders who have already voted do not need to take any action unless they wish to change their vote.

Key Dates

Keywords

proxy statement, executive compensation, total shareholder return, TSR, Seres Therapeutics, Pay Versus Performance, NEO, PEO, compensation, net income